{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T06:15:52Z","timestamp":1649139352252},"reference-count":27,"publisher":"American Society of Consultant Pharmacists","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2009,2,1]]},"DOI":"10.4140\/tcp.n.2009.146","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:16:08Z","timestamp":1294884968000},"page":"146-152","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Caring for Chronic Kidney Disease Patients: Focus on Mineral and Bone Disorders&lt;\/b&gt;"],"prefix":"10.4140","volume":"24","author":[{"given":"Timothy V.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Filson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2009,7,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"S Moe","year":"2006","journal-title":"Kidney Int"},{"key":"2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM199507203330307","article-title":"Renal osteodystrophy","volume":"333","author":"K Hruska","year":"1995","journal-title":"N Engl J Med"},{"key":"3","first-page":"1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42 Suppl 3","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"M Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"K Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"M Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"7","first-page":"119","article-title":"Improving phosphate-binder therapy as a way forward","volume":"19","author":"A Hutchinson","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ndt\/17.suppl_2.9","article-title":"The clinical impact of aluminum overload in renal failure","volume":"17","author":"J Cannata-Andia","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"9","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0272-6386(12)80496-3","article-title":"Calcium acetate control of serum phosphorus in hemodialysis patients","volume":"5","author":"M Emmett","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10","article-title":"Antacids (Calcium supplements)","volume-title":"USP DI: Drug Information for the Healthcare Professional","year":"2008"},{"key":"11","volume-title":"Phoslo (calcium acetate) package insert","year":"2003"},{"key":"12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1378\/chest.105.2.383","article-title":"Mitral valve calcification as an index of left ventricular dysfunction in patients with end stage renal disease on peritoneal dialysis","volume":"105","author":"J Huting","year":"1994","journal-title":"Chest"},{"key":"13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"G Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1523-1755.63.s85.28.x","article-title":"Vascular calcification in the uremic patient: a cardiovascular risk","volume":"63","author":"M Salgueira","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM198607173150304","article-title":"Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis","volume":"315","author":"E Slatopolsky","year":"1986","journal-title":"N Engl J Med"},{"key":"16","volume-title":"Renagel (sevelamer hydrochloride) package insert","year":"2007"},{"key":"17","volume-title":"Fosrenol (lanthanum carbonate) package insert","year":"2007"},{"key":"18","volume-title":"Rocaltrol (Calcitriol) package insert","year":"2004"},{"key":"19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0272-6386(01)80010-X","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1a-hydroxyvitamin D<sub>2<\/sub>) in dialysis patients with secondary hyperparathyroidism: a sequential comparison","volume":"37","author":"H Maung","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"20","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-nor-1-\u03b1-25-dihydroxyvitamin D<sub>2<\/sub> (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"K Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"S Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"22","first-page":"315","article-title":"A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease","volume":"56","author":"J Lindberg","year":"2001","journal-title":"Clin Nephrol"},{"key":"23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/ajkd.2001.28114","article-title":"Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism","volume":"38","author":"F Llach","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"24","volume-title":"Sensipar (Cinacalcet) package insert","year":"2008"},{"key":"25","volume-title":"Interpreting Laboratory Data. 2nd ed","author":"S Traub"},{"key":"26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/j.jrn.2005.11.001","article-title":"Enhanced foods: Hidden phosphorus and sodium in foods commonly eaten","volume":"16","author":"M Karalis","year":"2006","journal-title":"J Renal Nutr"},{"key":"27","unstructured":"27. Centers for Medicare & Medicaid Services. Department of Health and Human Services. 42 CFR Parts 405, 410, 413 et al. Medicare and Medicaid Programs; Conditions for Coverage for End-Stage Renal Disease Facilities; Final Rule. Released April 15, 2008. http:\/\/www.cms.hhs.gov\/CFCsAndCoPs\/13_ESRD.asp. Accessed September 4, 2008. <a target=\"_blank\" href='http:\/\/www.cms.hhs.gov\/CFCsAndCoPs\/13_ESRD.asp'>http:\/\/www.cms.hhs.gov\/CFCsAndCoPs\/13_ESRD.asp<\/a>"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T07:09:43Z","timestamp":1637132983000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2009\/00000024\/00000002\/art00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2,1]]}},"alternative-id":["5638080R55723622"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2009.146","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2,1]]}}}